Sanofi-Aventis Australia Pty Ltd
Yellow fever virus (YF17D)
Vaccine - altered antigen expression
This licence allows Sanofi-Aventis Australia Pty Ltd to commence the commercial supply of Dengvaxia, an attenuated GM dengue vaccine. Dengvaxia contains four GM attenuated viral strains to protect against the four main types of dengue virus. Dengvaxia is currently available in 14 countries. Some clinical trials of this vaccine were conducted in Australia between 2006 and 2012, authorised by the Gene Technology Regulator, a Human Ethics and Research Committee and the Therapeutic Goods Administration.
The Regulator has not imposed any specific measures to manage risk, as the risk assessment concluded that commercial supply of the GM vaccine poses negligible risks to the health and safety of people and the environment. However, general conditions have been imposed to ensure that there is ongoing oversight of the release. Commercial supply of vaccines in Australia will follow the Australian code of good wholesaling practice for medicines in schedules 2, 3, 4 & 8 (2011), the WHO’s Good Distribution Practices for pharmaceutical products (WHO 2010), and the Standard for the Uniform Scheduling of Medicines and Poisons (as current) which all provide appropriate controls and informed the risk assessment. Any unused vaccine or waste material will be disposed of in accordance with local requirements for clinical waste.
The risk analysis for this application was carried out in accordance with the Regulator’s Risk Analysis Framework.
Outlines the Regulator’s decision to issue a licence following the assessment of this application.
FAQs on the licence application and the Regulator’s decision to issue a licence for this application.
A summary of the Risk Assessment and Risk Management Plan prepared as part of the assessment of this application. It provides a brief description of the licence application, the risk assessment and risk management plan.
The final risk assessment and management plan prepared to support the Regulator's decision. It describes the GMO(s) and proposed work with the GMO(s) and provides an assessment of potential risks posed by the GMO(s). It also includes a summary of submissions received during the public consultation process.